Cardiotoxicity and capecitabine: a case report.
Oral fluoropyrimidines increasingly are being developed and studied as a novel treatment for breast, colorectal, and other cancers. Fluoropyrimidines are designed to generate 5-fluorouracil (5-FU) preferentially within tumors. Cardiotoxicity is a rare complication associated with 5-FU and oral fluoropyrimidine treatments. Chest pain is the most common presenting symptom, and, in many cases, the cardiotoxicity is partly or completely reversible. This article reviews fluoropyrimidine-induced cardiotoxicity and presents a case report of a woman who experienced this complication during capecitabine treatment.
Singer
Marybeth
M
mbs500@aol.com
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006334:Heart Function Tests; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000139:chemically induced* / Q000175:diagnosis*; D009367:Neoplasm Staging; D018570:Risk Assessment; D012720:Severity of Illness Index
D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil